RhumbLine Advisers
IDYA icon

RhumbLine Advisers’s IDEAYA Biosciences IDYA Stock Holding History

RhumbLine Advisers’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.68M Buy
121,930
+10,166
+9% +$384K ﹤0.01% 1464
2026
Q2 		$4.17M Buy
111,764
+4,381
+4% +$134K ﹤0.01% 1558
2026
Q1 		$3.58M Sell
107,383
-242
-0.2% -$8.12K ﹤0.01% 1573
2025
Q4 		$3.72M Sell
107,625
-17,226
-14% -$549K ﹤0.01% 1547
2025
Q3 		$3.4M Sell
124,851
-6,298
-5% -$152K ﹤0.01% 1621
2025
Q2 		$2.76M Buy
131,149
+6,712
+5% +$129K ﹤0.01% 1710
2025
Q1 		$2.04M Buy
124,437
+10,876
+10% +$232K ﹤0.01% 1800
2024
Q4 		$2.92M Buy
113,561
+585
+0.5% +$16.6K ﹤0.01% 1694
2024
Q3 		$3.58M Buy
112,976
+7,179
+7% +$272K ﹤0.01% 1600
2024
Q2 		$3.71M Buy
105,797
+9,387
+10% +$372K ﹤0.01% 1555
2024
Q1 		$4.23M Buy
96,410
+10,444
+12% +$449K ﹤0.01% 1495
2023
Q4 		$3.06M Buy
85,966
+7,172
+9% +$214K ﹤0.01% 1689
2023
Q3 		$2.13M Buy
78,794
+1,812
+2% +$46K ﹤0.01% 1822
2023
Q2 		$1.81M Buy
76,982
+7,771
+11% +$160K ﹤0.01% 1966
2023
Q1 		$950K Buy
69,211
+5,177
+8% +$86.2K ﹤0.01% 2149
2022
Q4 		$1.16M Buy
64,034
+10,356
+19% +$174K ﹤0.01% 2050
2022
Q3 		$801K Buy
53,678
+3,671
+7% +$47.7K ﹤0.01% 2263
2022
Q2 		$690K Buy
50,007
+10,025
+25% +$112K ﹤0.01% 2329
2022
Q1 		$447K Buy
39,982
+1,835
+5% +$27K ﹤0.01% 2472
2021
Q4 		$902K Buy
38,147
+2,887
+8% +$67.1K ﹤0.01% 2252
2021
Q3 		$899K Buy
35,260
+5,889
+20% +$138K ﹤0.01% 2274
2021
Q2 		$616K Buy
29,371
+10,763
+58% +$221K ﹤0.01% 2464
2021
Q1 		$437K Buy
18,608
+1,089
+6% +$21K ﹤0.01% 2553
2020
Q4 		$245K Buy
17,519
+3,849
+28% +$52.1K ﹤0.01% 2758
2020
Q3 		$172K Buy
13,670
+324
+2% +$4.01K ﹤0.01% 2732
2020
Q2 		$190K Buy
+13,346
New +$105K ﹤0.01% 2786

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

RhumbLine Advisers's IDYA Position: Q3 2026 in Review

RhumbLine Advisers increased its IDEAYA Biosciences (IDYA) stake by 9.1% in Q3 2026, buying an estimated $384K and bringing the position to 121,930 shares worth $4.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1464.

RhumbLine Advisers first reported a position in IDYA in Q2 2020 and has held it in 26 quarters since. 204 funds tracked by Wall St. Rank hold IDYA as of Q3 2026.

  • RhumbLine Advisers held 121,930 shares of IDEAYA Biosciences worth $4.68M as of Q3 2026.
  • RhumbLine Advisers bought 10,166 IDEAYA Biosciences shares in Q3 2026, an estimated $384K.
  • IDEAYA Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1464 holding.
  • RhumbLine Advisers first reported a position in IDEAYA Biosciences in Q2 2020 and has held it in 26 quarters since.
  • 204 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.